GAP Assessment for Waters Empower CSV documentation

A German pharmaceutical company approached Zamann requesting support as they needed technical consultancy to ensure that the CSV documentation related to the Waters Empower system was 100% compliant with the required standards and references. Therefore, we proposed a complete documentation evaluation, considering that this GAP Assessment process would be essential to ensure compliance with FDA regulations and GAMP guidelines. We offered a clear, self-explanatory, robust and holistic assessment of the entire environment surrounding CSV, and expert recommendations for remediation through CAPAs (Corrective and Preventive Actions).

Challenges Faced

Regulatory Scrutiny: The client’s computerized system was subject to FDA inspection, and any GAPs in validation documentation could result in significant findings or penalties.
Document Volume: The system’s validation documentation was extensive, including validation plans, protocols, testing scripts, and reports.
Complexity of Regulations: GAMP and FDA requirements are extensive and complex, requiring a deep understanding of risk-based approaches and lifecycle validation principles.
Time Sensitivity: The GAP Assessment needed to be completed within a short time frame to meet internal deadlines for regulatory submissions.

Zamann Pharma Support’s Approach

Project Initialization: Conducted an initial kick-off meeting with all related areas, to understand goals, timelines, and specific concerns. Review the current validation lifecycle documentation to map the scope of the GAP assessment.
Document Review: Each validation document was analyzed against FDA regulations and GAMP guidelines. Key focus documents including: User Requirements Specifications (URS), Functional Specifications (FS), Validation Master Plan (VMP), Test protocols/reports (IQ, OQ, PQ), Traceability matrices, and Change Control records.
Key Topics Evaluated: Risk assessments were compared against GAMP’s emphasis on risk-based validation. Testing protocols were checked for alignment with FDA expectations for data integrity, including audit trails and electronic signatures (21 CFR Part 11). Change management and deviation handling practices were evaluated for consistency and completeness.
Structured Findings: Delivered a detailed report with observations categorized into:
Critical GAPs: Direct non-conformances with FDA regulations or GAMP5 principles.
Major GAPs: Areas that could lead to regulatory observations if not addressed.
Minor GAPs: Opportunities to enhance documentation quality and robustness.
Corrective and Preventive Actions proposal: For each potential GAP, specific CAPAs were proposed, including: Revision of URS and FS to better reflect user needs and risk assessments. Updates to test protocols to ensure comprehensive testing of audit trails and electronic signature functionalities. Enhancements to traceability matrices to demonstrate complete coverage of user and functional requirements. Implementation of additional training for staff on validation principles and documentation practices. Update of some document templates, to facilitate their routine use, as well as the understanding of auditors.
Support for Implementation: Provided templates and examples to guide document revisions. Conducted workshops with the client’s team to ensure a clear understanding of CAPA execution. Establishment of a follow-up system to track CAPA progress.

Results Achieved

Regulatory Compliance: The GAP Assessment and proposed CAPAs brought the client’s validation documentation in line with FDA and GAMP5 requirements.
Improved Documentation: The client’s documentation was streamlined, making it easier to manage, review, and present during inspections.
Risk Mitigation: Identifying and addressing critical GAPs reduced the risk of regulatory findings or penalties.
Team Empowerment: By involving the client’s team in workshops and CAPA planning, they gained a deeper understanding of validation best practices and regulatory expectations.
Timely Completion: The assessment and remediation plan were completed on schedule, ensuring the client could meet their internal deadlines.

Services

Digital Solutions for GMP Operations

We support pharmaceutical teams in implementing, maintaining, and optimizing GMP software, data management systems, and computerized workflows that strengthen compliance, data integrity, and operational efficiency.

Contact Us

Need help? Don't hesitate to get in touch

First Name*

Last Name*

Email*

Phone number*

Role*

Department*

Country

Industry

Message

Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

Yes, I agree to receive personalized newsletters with market insights, invitations for exclusive events and educational webinars from the Zamann Pharma Support GmbH.

I consent to the privacy policy and understand that my personal data will be stored and processed*

FAQ

1. How do I check if my validation documents are FDA compliant?

Review your validation package against GAMP5 and FDA requirements. Focus on traceability, test evidence, audit trails, and alignment with 21 CFR Part 11 to identify compliance gaps.

2. What are the most common issues found during CSV inspections?

Inspectors often find missing traceability, incomplete testing, weak audit trails, and gaps in electronic signature compliance. These issues directly impact data integrity and inspection readiness.

3. How can CAPA improve compliance in computerized systems?

CAPA processes fix root causes by updating validation documents, strengthening testing, and improving data integrity controls. This ensures systems remain inspection-ready and fully compliant.

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com